AVXL (Anavex Life Sciences) PB Ratio: 1.87 (As of Jun. 25, 2026)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.56
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences PB Ratio?

Anavex Life Sciences AVXL -0.97% 30 PB Ratio is 1.87 as of Jun. 25, 2026. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Anavex Life Sciences ranks better than 64.64% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Anavex Life Sciences's share price is $2.56. Anavex Life Sciences's Book Value per Share for the quarter that ended in Dec. 2025 was $1.37. Hence, Anavex Life Sciences's PB Ratio of today is 1.87.

The historical rank and industry rank for Anavex Life Sciences's PB Ratio or its related term are showing as below:

AVXL' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.95
Current: 1.87

During the past 13 years, Anavex Life Sciences's highest PB Ratio was 1.95. The lowest was 0.00. And the median was 0.00.

AVXL's PB Ratio is ranked better than
64.64% of 1233 companies
in the Biotechnology industry
Industry Median: 2.83 vs AVXL: 1.87

During the past 12 months, Anavex Life Sciences's average Book Value Per Share Growth Rate was -22.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -15.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 10.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 21.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anavex Life Sciences was 227.10% per year. The lowest was -528.30% per year. And the median was 19.20% per year.

Back to Basics: PB Ratio


Anavex Life Sciences  (NAS:AVXL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Anavex Life Sciences PB Ratio Related Terms


Anavex Life Sciences PB Ratio Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences PB Ratio Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.03 5.65 3.79 4.01 8.13

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.23 7.34 8.66 8.13 2.61

AVXL vs ZNTL, HUMA, SABS: PB Ratio Comparison

For the Biotechnology subindustry, Anavex Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's PB Ratio falls into.


AVXL
30GF Score
Anavex Life Sciences Corp AVXL
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Anavex Life Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=2.56/1.366
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 1.87 mean?
Anavex Life Sciences (AVXL) has a PB Ratio of 1.87 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #436 out of 1233 companies in the Biotechnology industry, placing it in the top 35.4%.
Is Anavex Life Sciences' PB Ratio too high?
Anavex Life Sciences' current PB Ratio is 1.87. The Biotechnology industry median PB Ratio is 2.83. Anavex Life Sciences' value of 1.87 is 33.9% below this industry median. Based on the distribution chart, Anavex Life Sciences ranks #436 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' PB Ratio compare to ZNTL and HUMA?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #436 out of 1233 companies for PB Ratio. This puts Anavex Life Sciences in the upper half of its industry. The industry median PB Ratio is 2.83. Anavex Life Sciences' value of 1.87 is 33.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anavex Life Sciences's current PB Ratio of 1.87 is 33.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anavex Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anavex Life Sciences's current PB Ratio is 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current PB Ratio of 1.87. The current PB Ratio is 1.87 and 33.9% below the Biotechnology industry median of 2.83. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current PB Ratio is 1.87 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price